Top

European Journal of Nutrition

Published in:

Open Access 01-10-2020 | Respiratory Microbiota | Original Contribution

Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial

Authors: Eline Birkeland, Sedegheh Gharagozlian, Kåre I. Birkeland, Jørgen Valeur, Ingrid Måge, Ida Rud, Anne-Marie Aas

Published in: European Journal of Nutrition | Issue 7/2020

Abstract

Purpose

Compared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SCFA) in patients with type 2 diabetes.

Methods

The study was a placebo controlled crossover study, where 25 patients (15 men) aged 41–71 years consumed 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16-g placebo (maltodextrin) for 6 weeks in randomised order. A 4-week washout separated the 6 weeks treatments. The faecal microbiota was analysed by high-throughput 16S rRNA amplicon sequencing and SCFA in faeces were analysed using vacuum distillation followed by gas chromatography.

Results

Treatment with inulin-type fructans induced moderate changes in the faecal microbiota composition (1.5%, p = 0.045). A bifidogenic effect was most prominent, with highest positive effect on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by OTUs of Bacteroides. Significantly higher faecal concentrations of total SCFA, acetic acid and propionic acid were detected after prebiotic consumption compared to placebo. The prebiotic fibre had no effects on the concentration of butyric acid or on the overall microbial diversity.

Conclusion

Six weeks supplementation with inulin-type fructans had a significant bifidogenic effect and induced increased concentrations of faecal SCFA, without changing faecal microbial diversity. Our findings suggest a moderate potential of inulin-type fructans to improve gut microbiota composition and to increase microbial fermentation in type 2 diabetes.

Trial registration

The trial is registered at clinicaltrials.gov (NCT02569684).

Available only for authorised users

American Diabetes Association (2019) 5. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care 42(Suppl 1):S46–S60. https://doi.org/10.2337/dc19-S005CrossRef

Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ (2013) Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev 71(12):790–801. https://doi.org/10.1111/nure.12076CrossRefPubMed

Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L (2019) Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 393(10170):434–445. https://doi.org/10.1016/s0140-6736(18)31809-9CrossRefPubMed

Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75CrossRefPubMed

O'Callaghan A, van Sinderen D (2016) Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 7:925. https://doi.org/10.3389/fmicb.2016.00925CrossRefPubMedPubMedCentral

Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA (2016) Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol 5(4):e73. https://doi.org/10.1038/cti.2016.17CrossRef

Cani PD, Everard A, Duparc T (2013) Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol 13(6):935–940. https://doi.org/10.1016/j.coph.2013.09.008CrossRefPubMed

Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58(7):1509–1517. https://doi.org/10.2337/db08-1637CrossRefPubMedPubMedCentral

Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, Marsh DJ (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7(4):e35240. https://doi.org/10.1371/journal.pone.0035240CrossRefPubMedPubMedCentral

10.

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27(2):104–119. https://doi.org/10.1111/j.1365-2036.2007.03562.xCrossRefPubMed

11.

Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jorgensen T, Levenez F, Dore J, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581):262–266. https://doi.org/10.1038/nature15766CrossRefPubMedPubMedCentral

12.

Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452):99–103. https://doi.org/10.1038/nature12198CrossRefPubMed

13.

Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4):913–916. https://doi.org/10.1053/j.gastro.2012.06.031CrossRefPubMed

14.

Kolida S, Meyer D, Gibson GR (2007) A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr 61(10):1189–1195. https://doi.org/10.1038/sj.ejcn.1602636CrossRefPubMed

15.

Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourie B, Brouns F, Bornet FR (2004) The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr 80(6):1658–1664CrossRefPubMed

16.

Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Katan MB, van der Meer R (2006) Dietary fructooligosaccharides affect intestinal barrier function in healthy men. J Nutr 136(1):70–74. https://doi.org/10.1093/jn/136.1.70CrossRefPubMed

17.

Lomax AR, Cheung LV, Tuohy KM, Noakes PS, Miles EA, Calder PC (2012) Beta2-1 fructans have a bifidogenic effect in healthy middle-aged human subjects but do not alter immune responses examined in the absence of an in vivo immune challenge: results from a randomised controlled trial. Br J Nutr 108(10):1818–1828. https://doi.org/10.1017/s0007114511007276CrossRefPubMed

18.

Salazar N, Dewulf EM, Neyrinck AM, Bindels LB, Cani PD, Mahillon J, de Vos WM, Thissen JP, Gueimonde M, de Los Reyes-Gavilan CG, Delzenne NM (2014) Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr. https://doi.org/10.1016/j.clnu.2014.06.001CrossRefPubMed

19.

Healey G, Murphy R, Butts C, Brough L, Whelan K, Coad J (2018) Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study. Br J Nutr 119(2):176–189. https://doi.org/10.1017/s0007114517003440CrossRefPubMed

20.

Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM (2019) Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. MBio. https://doi.org/10.1128/mBio.02566-18CrossRefPubMedPubMedCentral

21.

Liu F, Li P, Chen M, Luo Y, Prabhakar M, Zheng H, He Y, Qi Q, Long H, Zhang Y, Sheng H, Zhou H (2017) Fructooligosaccharide (FOS) and galactooligosaccharide (GOS) increase Bifidobacterium but reduce butyrate producing bacteria with adverse glycemic metabolism in healthy young population. Sci Rep 7(1):11789. https://doi.org/10.1038/s41598-017-10722-2CrossRefPubMedPubMedCentral

22.

Vandeputte D, Falony G, Vieira-Silva S, Wang J, Sailer M, Theis S, Verbeke K, Raes J (2017) Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut 66(11):1968–1974. https://doi.org/10.1136/gutjnl-2016-313271CrossRefPubMed

23.

Holscher HD, Bauer LL, Gourineni V, Pelkman CL, Fahey GC Jr, Swanson KS (2015) Agave inulin supplementation affects the fecal microbiota of healthy adults participating in a randomized, double-blind, placebo-controlled, crossover trial. J Nutr 145(9):2025–2032. https://doi.org/10.3945/jn.115.217331CrossRefPubMed

24.

Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P (2009) Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 101(4):541–550. https://doi.org/10.1017/s0007114508019880CrossRefPubMed

25.

Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N (2020) Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051CrossRefPubMedPubMedCentral

26.

Mahboobi S, Rahimi F, Jafarnejad S (2018) Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Adv Pharm Bull 8(4):565–574. https://doi.org/10.15171/apb.2018.065CrossRefPubMedPubMedCentral

27.

Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourie B, Bornet F, Rambaud JC (1999) Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 129(1):113–116CrossRefPubMed

28.

Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De Backer F, Neyrinck AM, Delzenne NM (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90(5):1236–1243. https://doi.org/10.3945/ajcn.2009.28095CrossRefPubMed

29.

Carlsen MH, Lillegaard IT, Karlsen A, Blomhoff R, Drevon CA, Andersen LF (2010) Evaluation of energy and dietary intake estimates from a food frequency questionnaire using independent energy expenditure measurement and weighed food records. Nutr J 9:37. https://doi.org/10.1186/1475-2891-9-37CrossRefPubMedPubMedCentral

30.

Carlsen MH, Karlsen A, Lillegaard IT, Gran JM, Drevon CA, Blomhoff R, Andersen LF (2011) Relative validity of fruit and vegetable intake estimated from an FFQ, using carotenoid and flavonoid biomarkers and the method of triads. Br J Nutr 105(10):1530–1538. https://doi.org/10.1017/s0007114510005246CrossRefPubMed

31.

Moen B, Henjum K, Mage I, Knutsen SH, Rud I, Hetland RB, Paulsen JE (2016) Effect of dietary fibers on cecal microbiota and intestinal tumorigenesis in azoxymethane treated A/J Min/+ mice. PLoS ONE 11(5):e0155402. https://doi.org/10.1371/journal.pone.0155402CrossRefPubMedPubMedCentral

32.

Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R (2012) Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 6(8):1621–1624. https://doi.org/10.1038/ismej.2012.8CrossRefPubMedPubMedCentral

33.

Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, Gilbert JA, Jansson JK, Caporaso JG, Fuhrman JA, Apprill A, Knight R (2016) Improved bacterial 16S rRNA Gene (V4 and V4–5) and fungal internal transcribed spacer marker gene primers for microbial community surveys. mSystems. https://doi.org/10.1128/mSystems.00009-15CrossRefPubMed

34.

Parada AE, Needham DM, Fuhrman JA (2016) Every base matters: assessing small subunit rRNA primers for marine microbiomes with mock communities, time series and global field samples. Environ Microbiol 18(5):1403–1414. https://doi.org/10.1111/1462-2920.13023CrossRefPubMed

35.

Apprill A, McNally S, Parsons R, Weber L (2015) Minor revision to V4 region SSU rRNA 806R gene primer greatly increases detection of SAR11 bacterioplankton. Aquat Microb Ecol 75:129–137. https://doi.org/10.3354/ame01753CrossRef

36.

Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7(5):335–336. https://doi.org/10.1038/nmeth.f.303CrossRefPubMedPubMedCentral

37.

Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J (1977) Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta 78(2):243–250CrossRefPubMed

38.

Hoverstad T, Fausa O, Bjorneklett A, Bohmer T (1984) Short-chain fatty acids in the normal human feces. Scand J Gastroenterol 19(3):375–381CrossRefPubMed

39.

Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K (2015) Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 3(3):191–197. https://doi.org/10.1016/s2213-8587(14)70251-7CrossRefPubMed

40.

Jansen JJ, Hoefsloot HCJ, van der Greef J, Timmerman ME, Westerhuis JA, Smilde AK (2005) ASCA: analysis of multivariate data obtained from an experimental design. J Chemometr 19(9):469–481. https://doi.org/10.1002/cem.952CrossRef

41.

Eriksson L, Byrne T, Johansson E, Trygg J, Vikström C (2013) Multi- and megavariate data analysis: basic principles and applications

42.

Wilson B, Whelan K (2017) Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. J Gastroenterol Hepatol 32(Suppl 1):64–68. https://doi.org/10.1111/jgh.13700CrossRefPubMed

43.

Ghoddusi HB, Grandison MA, Grandison AS, Tuohy KM (2007) In vitro study on gas generation and prebiotic effects of some carbohydrates and their mixtures. Anaerobe 13(5–6):193–199. https://doi.org/10.1016/j.anaerobe.2007.06.002CrossRefPubMed

44.

Sanders ME, Lenoir-Wijnkoop I, Salminen S, Merenstein DJ, Gibson GR, Petschow BW, Nieuwdorp M, Tancredi DJ, Cifelli CJ, Jacques P, Pot B (2014) Probiotics and prebiotics: prospects for public health and nutritional recommendations. Ann N Y Acad Sci 1309(1):19–29. https://doi.org/10.1111/nyas.12377CrossRefPubMed

45.

Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50(11):2374–2383. https://doi.org/10.1007/s00125-007-0791-0CrossRefPubMed

46.

Cronin M, Ventura M, Fitzgerald GF, van Sinderen D (2011) Progress in genomics, metabolism and biotechnology of bifidobacteria. Int J Food Microbiol 149(1):4–18. https://doi.org/10.1016/j.ijfoodmicro.2011.01.019CrossRefPubMed

47.

Tandon D, Haque MM, Gote M, Jain M, Bhaduri A, Dubey AK, Mande SS (2019) A prospective randomized, double-blind, placebo-controlled, dose-response relationship study to investigate efficacy of fructo-oligosaccharides (FOS) on human gut microflora. Sci Rep 9(1):5473. https://doi.org/10.1038/s41598-019-41837-3CrossRefPubMedPubMedCentral

48.

Parnell JA, Reimer RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89(6):1751–1759. https://doi.org/10.3945/ajcn.2009.27465CrossRefPubMed

49.

Genta S, Cabrera W, Habib N, Pons J, Carillo IM, Grau A, Sanchez S (2009) Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr (Edinburgh, Scotland) 28(2):182–187. https://doi.org/10.1016/j.clnu.2009.01.013CrossRef

50.

Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7(3):189–200. https://doi.org/10.1080/19490976.2015.1134082CrossRefPubMedPubMedCentral

51.

Scheppach W, Weiler F (2004) The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 7(5):563–567CrossRefPubMed

52.

Moens F, Weckx S, De Vuyst L (2016) Bifidobacterial inulin-type fructan degradation capacity determines cross-feeding interactions between bifidobacteria and Faecalibacterium prausnitzii. Int J Food Microbiol 231:76–85. https://doi.org/10.1016/j.ijfoodmicro.2016.05.015CrossRefPubMed

53.

Rios-Covian D, Gueimonde M, Duncan SH, Flint HJ, de los Reyes-Gavilan CG (2015) Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett 362(21):78. https://doi.org/10.1093/femsle/fnv176CrossRef

54.

Rossi M, Corradini C, Amaretti A, Nicolini M, Pompei A, Zanoni S, Matteuzzi D (2005) Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures. Appl Environ Microbiol 71(10):6150–6158. https://doi.org/10.1128/aem.71.10.6150-6158.2005CrossRefPubMedPubMedCentral

55.

Falony G, Lazidou K, Verschaeren A, Weckx S, Maes D, De Vuyst L (2009) In vitro kinetic analysis of fermentation of prebiotic inulin-type fructans by Bifidobacterium species reveals four different phenotypes. Appl Environ Microbiol 75(2):454–461. https://doi.org/10.1128/aem.01488-08CrossRefPubMed

56.

Sonnenburg ED, Zheng H, Joglekar P, Higginbottom SK, Firbank SJ, Bolam DN, Sonnenburg JL (2010) Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 141(7):1241–1252. https://doi.org/10.1016/j.cell.2010.05.005CrossRefPubMedPubMedCentral

57.

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505(7484):559–563. https://doi.org/10.1038/nature12820CrossRefPubMed

58.

Aas A-M, Johansson L, Bjerkan K, Lorentsen N, Mostad I (2013) Do Norwegians with diabetes have a healthier diet than the general population? Norsk Epidemiol 23:61–74. https://doi.org/10.5324/nje.v23i1.1604CrossRef

59.

Tuohy KM, Kolida S, Lustenberger AM, Gibson GR (2001) The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides—a human volunteer study. Br J Nutr 86(3):341–348CrossRefPubMed

60.

de Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K (2008) Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects. Aliment Pharmacol Ther 27(6):504–513. https://doi.org/10.1111/j.1365-2036.2007.03588.xCrossRefPubMed

Title: Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
Authors: Eline Birkeland
Sedegheh Gharagozlian
Kåre I. Birkeland
Jørgen Valeur
Ingrid Måge
Ida Rud
Anne-Marie Aas
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Respiratory Microbiota
Type 2 Diabetes
Published in: European Journal of Nutrition / Issue 7/2020
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-020-02282-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 7/2020

The impact of food additives, artificial sweeteners and domestic hygiene products on the human gut microbiome and its fibre fermentation capacity

Changes of trace element status during aging: results of the EPIC-Potsdam cohort study

A systematic review and meta-analysis of 24-h urinary output of children and adolescents: impact on the assessment of iodine status using urinary biomarkers

Egg yolk augments type 2 immunity by activating innate cells

Time course of tolerance to adverse effects associated with the ingestion of a moderate dose of caffeine

Adipose tissue content of alpha-linolenic acid and development of peripheral artery disease: a Danish case-cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page